Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and doctor appointments.

Dr. Leora Horn

Dr. Leora Horn

Clinical Director, Thoracic Oncology Program

Dr. Leora Horn is the clinical director of the Thoracic Oncology Program at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

Get in touch
Jump to a Topic:

About Leora Horn

  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Team Leader icon

    Team Leader

  • Research Excellence icon

    Excellence in Research

  • Board Certified icon

    Board Certified in Medical Oncology

As an oncologist, Horn focuses her clinical practice on patients with lung cancer, pleural mesothelioma and thymic cancer. She is the principal investigator on several ongoing clinical trials that target those cancers.

Horn also is an associate professor of medicine at Vanderbilt University and the assistant director of the Educator Development Program, designed to enhance the knowledge, skills and attitudes of Medical Center faculty.

Much of her research focuses on experimental therapeutics, and she has received a Vanderbilt-Ingram Impact Award for her work. The National Cancer Institute further awarded her with a Cancer Clinical Investigator Team Leadership Award in 2015.

Horn received her medical degree from the University of Toronto, where she also did a fellowship in Internal Medicine that was funded by the Canadian Association of Medical Oncology. She did a second fellowship at Vanderbilt-Ingram, where now she has taken a leadership role.

Running Clinical Trials for New Drug Combinations

Horn’s latest Phase I/II clinical trial for lung cancer started in August 2018. It involves a combination of Opdivo (nivolumab), the popular immunotherapy drug, and Vorolanib, a vascular growth-factor inhibitor.

If successful, the same combination may be tried for mesothelioma.

Horn took the lead in an earlier clinical trial involving a similar combination of Gilotrif (afatanib) and Portrazza (necitumumab) that targets specific tumor mutations.

The study was funded by the National Comprehensive Cancer Network, which is an alliance of leading cancer centers around the world dedicated to research and patient care.

“We are now testing a novel drug combination to determine if we can produce a more durable response to prolong and enhance our patients’ lives,” she said in a press release announcing the trial.

Horn has published more than 30 book chapters and papers, most on her research into lung cancer.

She is a member of the Royal College of Physicians and Surgeons of Canada and the American Society of Clinical Oncology. She is board certified in Internal Medicine.

Disclaimer: Dr. Leora Horn has no professional affiliation with

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. Mesothelioma Packet

Get a Free Treatment Guide Sent Overnight

Get Yours Now

Find Ways to Pay for Treatment Costs

Get Started

Find an Active Mesothelioma Clinical Trial

Find Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Walter Pacheco, Managing Editor at
Edited by

3 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Vanderbilt University Medical Center. (n.d.). Leora Horn M.D., M.Sc.
    Retrieved from:
  2. Vanderbilt Health. (n.d.). Doctor Directory.
    Retrieved from:
  3. VUMC Reporter. (2017, March 30). Horn to lead lung cancer combination therapy trial. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified July 30, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now